Leptomeningeal metastasis is a consequence of advanced solid malignancies and has
limited treatment options. It is possible that it is becoming more common as the
leptomeninges act as a sanctuary site for recurrence from systemic cancer.
Methods
Potential targeted and immunotherapy agents for the most common types of solid-tumor
leptomeningeal metastasis are reviewed, as are their dosing/delivery strategies and
novel, immunological approaches.
Results
Historically, patients with leptomeningeal metastasis have been excluded from clinical
trials, and data on the management of leptomeningeal metastasis come from single case
reports and retrospective analyses.
Conclusion
For the first time ever, published reports suggest the tide may be turning in this
challenging disease.
References
1.
Le
RhunE.,
TaillibertS.,
ChamberlainM.C.Carcinomatous meningitis: leptomeningeal metastases in solid
tumors.Surg Neurol Int.2013; 4(suppl 4):
S265–S288.
2.
ParkJ.H.,
KimY.J.,
LeeJ.O.Clinical outcomes of leptomeningeal metastasis in patients with non-small
cell lung cancer in the modern chemotherapy era.Lung Cancer.2012; 76(3):
387–392.
3.
WilgenhofS.,
NeynsB.Complete cytologic remission of V600E BRAF-mutant melanoma-associated
leptomeningeal carcinomatosis upon treatment with dabrafenib.J Clin Oncol.2015; 33(28):
e109–e111.
4.
SchäferN.,
SchefflerB.,
StuplichM.Vemurafenib for leptomeningeal melanomatosis.J Clin Oncol.2013; 31(11):
e173–e174.
5.
LeeJ.M.,
MehtaU.N.,
DsouzaL.H.Long-term stabilization of leptomeningeal disease with whole-brain
radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case
report.Melanoma Res.2013; 23(2):
175–178.
6.
JackmanD.M.,
HolmesA.J.,
LindemanN.Response and resistance in a non-small-cell lung cancer patient with an
epidermal growth factor receptor mutation and leptomeningeal metastases treated with
high-dose gefitinib.J Clin Oncol.2006; 24(27):
4517–4520.
7.
LinC.H.,
LinM.T.,
KuoW.Y.Afatinib combined with cetuximab for lung adenocarcinoma with
leptomeningeal carcinomatosis.Lung Cancer.2014; 85(3):
479–480.
8.
ArrondeauJ.,
AmmariS.,
BesseB.LDK378 compassionate use for treating carcinomatous meningitis in an ALK
translocated non-small-cell lung cancer.J Thorac Oncol.2014; 9(8):
e62–e63.
9.
GainorJ.F.,
ShermanC.A.,
WilloughbyK.Alectinib salvages CNS relapses in ALK-positive lung cancer patients
previously treated with crizotinib and ceritinib.J Thorac Oncol.2015; 10(2):
232–236.
10.
PlatiniC.,
LongJ.,
WalterS.Meningeal carcinomatosis from breast cancer treated with intrathecal
trastuzumab.Lancet Oncol.2006; 7(9):
778–780.
11.
GrommesC.,
OxnardG.R.,
KrisM.G.Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant
non-smallcell lung cancer.Neuro Oncol.2011; 13(12):
1364–1369.
12.
CessotA.,
BlanchetB.,
GoldwasserF.Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is
better.Ann Oncol.2014; 25(10):
2093–2094.
13.
KuiperJ.L.,
SmitE.F.High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal
metastases–one with a remarkable thoracic response as well.Lung Cancer.2013; 80(1):
102–105.
14.
YuanY.,
TanC.,
LiM.Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung
adenocarcinoma with brain and leptomeningeal metastasis after response to
gefitinib.World J Surg Oncol.2012; 10: 235.
15.
StemmlerH.J.,
MengeleK.,
SchmittM.Intrathecal trastuzumab and methotrexate for meningeal carcinomatosis in
HER2-overexpressing metastatic breast cancer: a case report.Anticancer Drugs.2008; 19(8):
832–836.
16.
FerrarioC.,
DavidsonA.,
BouganimN.Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast
cancer.Ann Oncol.2009; 20(4):
792–795.
17.
MartensJ.,
VenuturumilliP.,
CorbetsL.Rapid clinical and radiographic improvement after intrathecal trastuzumab
and methotrexate in a patient with HER-2 positive leptomeningeal
metastases.Acta Oncol.2013; 52(1):
175–178.
18.
ZagouriF.,
SergentanisT.N.,
BartschR.Intrathecal administration of trastuzumab for the treatment of meningeal
carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled
analysis.Breast Cancer Res Treat.2013; 139(1):
13–22.
19.
GibneyG.T.,
GauthierG.,
AyasC.Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with
brain metastases receiving vemurafenib in the real-world setting.Cancer Med.2015; 4(8):
1205–1213.
20.
Sakji-DupréL.,
Le RhunE.,
TemplierC.Cerebrospinal fluid concentrations of vemurafenib in patients treated for
brain metastatic BRAF-V600 mutated melanoma.Melanoma Res.2015; 25(4):
302–305.
21.
LongG.V.,
TrefzerU.,
DaviesM.A.Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma
metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2
trial.Lancet Oncol.2012; 13(11):
1087–1095.
22.
ClarkeJ.L.,
PaoW.,
WuN.High dose weekly erlotinib achieves therapeutic concentrations in CSF and
is effective in leptomeningeal metastases from epidermal growth factor receptor mutant
lung cancer.J Neurooncol.2010; 99(2):
283–286.
23.
JanjigianY.Y.,
SmitE.F.,
GroenH.J.Dual inhibition of EGFR with afatinib and cetuximab in kinase
inhibitor-resistant EGFR-mutant lung cancer with and without T790M
mutations.Cancer Discov.2014; 4(9):
1036–1045.
24.
GainorJ.F.,
OuS.H.,
LoganJ.The central nervous system as a sanctuary site in ALK-positive
non-small-cell lung cancer.J Thorac Oncol.2013; 8(12):
1570–1573.
25.
DziadziuszkoR.,
JassemJ.Beneath the blood brain barrier: the challenge of diagnosis and management
of central nervous system involvement in ALK-positive lung cancer.J Thorac Oncol.2013; 8(12):
1465–1466.
Ceritinib [package insert].Novartis Pharmaceuticals: East Hanover,
NJ; 2016.
28.
KodamaT.,
HasegawaM.,
TakanashiK.Antitumor activity of the selective ALK inhibitor alectinib in models of
intracranial metastases.Cancer Chemother Pharmacol.2014; 74(5):
1023–1028.
29.
OuS.I.,
AhnJ.S., De
PetrisL.Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung
cancer: a phase II global study.J Clin Oncol.2016; 34(7)
661–668.
30.
ZouH.Y.,
FribouletL.,
KodackD.P.PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and
second generation ALK inhibitors in preclinical models.Cancer Cell.2015; 28(1):
70–81.
31.
BendellJ.C.,
DomchekS.M.,
BursteinH.J.Central nervous system metastases in women who receive trastuzumab-based
therapy for metastatic breast carcinoma.Cancer.2003; 97(12):
2972–2977.
32.
Di
GiacomoA.M.,
AsciertoP.A.,
PillaL.Ipilimumab and fote-mustine in patients with advanced melanoma (NIBIT-M1):
an open-label, single-arm phase 2 trial.Lancet Oncol.2012; 13(9):
879–886.
33.
MargolinK.,
ErnstoffM.S.,
HamidO.Ipilimumab in patients with melanoma and brain metastases: an open-label,
phase 2 trial.Lancet Oncol.2012; 13(5):
459–465.
34.
BotI.,
BlankC.U.,
BrandsmaD.Clinical and radiological response of leptomeningeal melanoma after whole
brain radiotherapy and ipilimumab.J Neurol.2012; 259(9):
1976–1978.
35.
GlitzaI.C.,
RohlfsM.,
BassettR.Therapeutic outcomes of intrathecal interleukin-2 in metastatic melanoma
patients with leptomeningeal disease (LMD).Neuro Oncol.2015; 17:
v107–112.
36.
ZikichD.,
SchachterJ.,
BesserM.J.Predictors of tumor-infiltrating lymphocyte efficacy in
melanoma.Immunotherapy.2016; 8(1):
35–43.
37.
GlitzaI.C.,
HaymakerC.,
BernatchezC.Intrathecal administration of tumor-infiltrating lymphocytes is well
tolerated in a patient with leptomeningeal disease from metastatic melanoma: a case
report.Cancer Immunol Res.2015; 3(11):
1201–1206.
38.
Clemons-MillerA.R.,
ChattaG.S.,
HutchinsL.Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal
melanoma.Clin Cancer Res.2001; 7:
917s–924s.
